Download PDF
Eur J Pediatr Surg 2019; 29(01): 001-006
DOI: 10.1055/s-0038-1668146
Original Article
Georg Thieme Verlag KG Stuttgart · New York

What Happens after Kasai for Biliary Atresia? A European Multicenter Survey

Zeng Hao Wong
1   Department of Paediatric Surgery, King's College Hospital, London, United Kingdom
,
Mark Davenport
1   Department of Paediatric Surgery, King's College Hospital, London, United Kingdom
› Author Affiliations
Further Information

Publication History

15 May 2018

26 June 2018

Publication Date:
21 August 2018 (online)

   Permissions and Reprints

Abstract

Aim Biliary atresia (BA) remains a rare disease in Europe with an estimated incidence of 1 in 15–20,000 livebirths. While the Kasai portoenterostomy (KPE) is regarded as the standard operation for BA, there is no consensus on optimum adjuvant therapy. We sought to determine the variation in therapy and opinion in centers known to have an interest in pediatric hepatobiliary surgery across Europe.

Methods A survey of current pre- and postoperative practice was circulated to surgeons and centers known to have an interest in BA. Data are quoted as median (range).

Results There were 19 completed center forms from 12 different countries. Annual (new) caseload varied with 10 centers reported seeing ≤5 patients/year and 4 centers >15 patients/year. The distribution of BA variants was isolated BA (80 [60–100]%), syndromic BA (10 [3–35]%), cystic BA (5 [1–15]%), and cytomegalovirus (CMV) immunoglobulin M (IgM)-positive BA (5 [0–15]% (CMV serology only formally tested in 16 centers). The commonest age group at KPE was 51 to 60 days (n = 8). All centers performed an exclusively open KPE, although one used laparoscopy for diagnosis. A steroid-based postoperative regimen was used in 11/19 (58%) centers, but with marked variation in dose and duration. Commonest perioperative antibiotics were a combination of piperacillin-tazocin (n = 7) and gentamicin (n = 8). Oral prophylactic antibiotics, with varying duration (4–52 weeks) were used in 13/19 (68%) centers. If CMV serology was positive, seven centers would treat with specific antiviral therapy. Other postoperative medication included ursodeoxycholic acid (UDCA) (n = 19), phenobarbitone (n = 4), and cholestyramine (n = 2). Self-declared clearance of jaundice in centers varied from 30 to 40% (n = 3) to > 60% (n = 5).

Conclusion All surveyed European centers continue to perform an exclusively open KPE, but there is no consensus on a standard adjuvant drug regimen. Self-declared outcome post-KPE also appears to be variable though the reasons are obscure.

Keywords

biliary atresia - adjuvant therapy - Kasai portoenterostomy - corticosteroids - ursodeoxycholic acid

Supplementary Material

 

  • References

  • 1 Hsiao C-H, Chang M-H, Chen H-L. , et al; Taiwan Infant Stool Color Card Study Group. Universal screening for biliary atresia using an infant stool color card in Taiwan. Hepatology 2008; 47 (04) 1233-1240
    Google Scholar
  • 2 Nio M. Japanese Biliary Atresia Registry. Pediatr Surg Int 2017; 33 (12) 1319-1325
    CrossrefPubMedGoogle Scholar
  • 3 Fischler B, Haglund B, Hjern A. A population-based study on the incidence and possible pre- and perinatal etiologic risk factors of biliary atresia. J Pediatr 2002; 141 (02) 217-222
    CrossrefPubMedGoogle Scholar
  • 4 Wildhaber BE, Majno P, Mayr J. , et al. Biliary atresia: Swiss national study, 1994-2004. J Pediatr Gastroenterol Nutr 2008; 46 (03) 299-307
    CrossrefPubMedGoogle Scholar
  • 5 Livesey E, Cortina Borja M, Sharif K. , et al. Epidemiology of biliary atresia in England and Wales (1999-2006). Arch Dis Child Fetal Neonatal Ed 2009; 94 (06) F451-F455
    CrossrefPubMedGoogle Scholar
  • 6 Chardot C, Carton M, Spire-Bendelac N, Le Pommelet C, Golmard JL, Auvert B. Epidemiology of biliary atresia in France: a national study 1986-96. J Hepatol 1999; 31 (06) 1006-1013
    CrossrefPubMedGoogle Scholar
  • 7 Zani A, Quaglia A, Hadzić N, Zuckerman M, Davenport M. Cytomegalovirus-associated biliary atresia: an aetiological and prognostic subgroup. J Pediatr Surg 2015; 50 (10) 1739-1745
    CrossrefPubMedGoogle Scholar
  • 8 Ure BM, Kuebler JF, Schukfeh N, Engelmann C, Dingemann J, Petersen C. Survival with the native liver after laparoscopic versus conventional Kasai portoenterostomy in infants with biliary atresia: a prospective trial. Ann Surg 2011; 253 (04) 826-830
    CrossrefPubMedGoogle Scholar
  • 9 Oetzmann von Sochaczewski C, Petersen C, Ure BM. , et al. Laparoscopic versus conventional Kasai portoenterostomy does not facilitate subsequent liver transplantation in infants with biliary atresia. J Laparoendosc Adv Surg Tech A 2012; 22 (04) 408-411
    CrossrefPubMedGoogle Scholar
  • 10 Davenport M, Stringer MD, Tizzard SA, McClean P, Mieli-Vergani G, Hadzic N. Randomized, double-blind, placebo-controlled trial of corticosteroids after Kasai portoenterostomy for biliary atresia. Hepatology 2007; 46 (06) 1821-1827
    CrossrefPubMedGoogle Scholar
  • 11 Bezerra JA, Spino C, Magee JC. , et al; Childhood Liver Disease Research and Education Network (ChiLDREN). Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial. JAMA 2014; 311 (17) 1750-1759
    CrossrefPubMedGoogle Scholar
  • 12 Petersen C, Harder D, Melter M. , et al. Postoperative high-dose steroids do not improve mid-term survival with native liver in biliary atresia. Am J Gastroenterol 2008; 103 (03) 712-719
    CrossrefPubMedGoogle Scholar
  • 13 Davenport M, Parsons C, Tizzard S, Hadzic N. Steroids in biliary atresia: single surgeon, single centre, prospective study. J Hepatol 2013; 59 (05) 1054-1058
    CrossrefPubMedGoogle Scholar
  • 14 Chen Y, Nah SA, Chiang L, Krishnaswamy G, Low Y. Postoperative steroid therapy for biliary atresia: Systematic review and meta-analysis. J Pediatr Surg 2015; 50 (09) 1590-1594
    CrossrefPubMedGoogle Scholar
  • 15 Tyraskis A, Davenport M. Steroids after the Kasai procedure for biliary atresia: the effect of age at Kasai portoenterostomy. Pediatr Surg Int 2016; 32 (03) 193-200
    CrossrefPubMedGoogle Scholar
  • 16 Yamashiro Y, Ohtsuka Y, Shimizu T. , et al. Effects of ursodeoxycholic acid treatment on essential fatty acid deficiency in patients with biliary atresia. J Pediatr Surg 1994; 29 (03) 425-428
    CrossrefPubMedGoogle Scholar
  • 17 Mousa HS, Lleo A, Invernizzi P, Bowlus CL, Gershwin ME. Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opin Pharmacother 2015; 16 (05) 633-643
    CrossrefPubMedGoogle Scholar
  • 18 Willot S, Uhlen S, Michaud L. , et al. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia. Pediatrics 2008; 122 (06) e1236-e1241
    CrossrefPubMedGoogle Scholar
  • 19 Vajro P, Couturier M, Lemonnier F, Odièvre M. Effects of postoperative cholestyramine and phenobarbital administration on bile flow restoration in infants with extrahepatic biliary atresia. J Pediatr Surg 1986; 21 (04) 362-365
    CrossrefPubMedGoogle Scholar
  • 20 de Vries W, de Langen ZJ, Groen H. , et al; Netherlands Study Group of Biliary Atresia and Registry (NeSBAR). Biliary atresia in the Netherlands: outcome of patients diagnosed between 1987 and 2008. J Pediatr 2012; 160 (04) 638-644
    CrossrefPubMedGoogle Scholar
  • 21 Bu L-N, Chen H-L, Chang C-J. , et al. Prophylactic oral antibiotics in prevention of recurrent cholangitis after the Kasai portoenterostomy. J Pediatr Surg 2003; 38 (04) 590-593
    CrossrefPubMedGoogle Scholar
  • 22 Decharun K, Leys CM, West KW, Finnell SME. Prophylactic antibiotics for prevention of cholangitis in patients with biliary atresia status post-Kasai portoenterostomy: a systematic review. Clin Pediatr (Phila) 2016; 55 (01) 66-72
    CrossrefPubMedGoogle Scholar
  • 23 Shen C, Zheng S, Wang W, Xiao X-M. Relationship between prognosis of biliary atresia and infection of cytomegalovirus. World J Pediatr 2008; 4 (02) 123-126
    CrossrefPubMedGoogle Scholar
  • 24 Kimberlin DW, Jester PM, Sánchez PJ. , et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372 (10) 933-943
    CrossrefPubMedGoogle Scholar
  • 25 Fischler B, Svensson JF, Nemeth A. Early cytomegalovirus infection and the long-term outcome of biliary atresia. Acta Paediatr 2009; 98 (10) 1600-1602
    CrossrefPubMedGoogle Scholar
  • 26 Schukfeh N, Al-Gamrah A, Petersen C, Kuebler JF. Detection of hepatotropic viruses has no impact on the prognosis after Kasai procedure. J Pediatr Surg 2012; 47 (10) 1828-1832
    CrossrefPubMedGoogle Scholar
  • 27 Tamura T, Kobayashi H, Yamataka A, Lane GJ, Koga H, Miyano T. Inchin-ko-to prevents medium-term liver fibrosis in postoperative biliary atresia patients. Pediatr Surg Int 2007; 23 (04) 343-347
    CrossrefPubMedGoogle Scholar
  • 28 Chardot C, Buet C, Serinet MO. , et al. Improving outcomes of biliary atresia: French national series 1986-2009. J Hepatol 2013; 58 (06) 1209-1217
    CrossrefPubMedGoogle Scholar
  • 29 Davenport M, Ong E, Sharif K. , et al. Biliary atresia in England and Wales: results of centralization and new benchmark. J Pediatr Surg 2011; 46 (09) 1689-1694
    CrossrefPubMedGoogle Scholar
  • 30 Pakarinen MP, Johansen LS, Svensson JF. , et al; Nordic Pediatric Surgery Study Consortium. Outcomes of biliary atresia in the Nordic countries – a multicenter study of 158 patients during 2005-2016. J Pediatr Surg 2018; 53 (08) 1509-1515
    CrossrefPubMedGoogle Scholar
  • 31 Zani A, Zani-Ruttenstock E, Eaton S, Pierro A. The value of surveys in pediatric surgery. Eur J Pediatr Surg 2015; 25 (06) 500-503
    Article in Thieme ConnectPubMedGoogle Scholar